pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Quillivant XR
drug
save

Quillivant XR

Marketedupdated 2mo ago
by Tris Pharma Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval430 co-mentions · 201 sources
  • drugMETADATE CD406 co-mentions · 206 sources
  • drugMETADATE ER262 co-mentions · 206 sources
  • drugRITALIN LA245 co-mentions · 206 sources
  • drugMethylin233 co-mentions · 206 sources
  • drugMETHYLIN ER233 co-mentions · 206 sources
  • drugmethylphenidate hydrochloride ER225 co-mentions · 206 sources
  • drugRelexxii223 co-mentions · 206 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Quillivant XR

  • phase3Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHDterminatedn=26
  • phase1Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditionscompletedn=24
  • phase1Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditionscompletedn=24
  • phase4A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbiditycompletedn=60

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 29, 2029
~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (7)

  • Feb 15, 2031formulationUS 82879034.6y
  • Feb 15, 2031formulationUS 84657654.6y
  • Feb 15, 2031formulationUS 85630334.6y
  • Feb 15, 2031formulationUS 87783904.6y
  • Feb 15, 2031formulationUS 89566494.6y
  • Feb 15, 2031formulationUS 90400834.6y
  • Mar 29, 2029formulationUS 80626672.7y

News(0)

no news has mentioned this drug yet

brand
Quillivant XR
generic
methylphenidate hydrochloride
indication
Attention Deficit Hyperactivity Disorder (ADHD)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 49m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?